Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;10(3):456. doi: 10.3390/antiox10030456

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Quantification of mVEC proliferation after treatment with CTLA-2 alpha or anti CTLA-2 alpha neutralizing antibody. (a) Proliferation of mVECs following treatment with PBS or CTLA-2 alpha, analyzed using an XTT cell proliferation assay kit. Cell proliferation is indicated by the absorbance (* p = 0.0286; n = 4). (b) Effects of CTLA-2 alpha and an antiCTLA-2 alpha antibody on mVEC proliferation; iso, 1 µg of iso-type control; ab, 1 µg of CTLA-2 alpha neutralizing antibody (* p = 0.0286; n = 4). (c) Effects of CTLA-2 alpha overexpression on mVEC proliferation in vitro (n = 5). CTLA-2 alpha, CTLA-2 alpha overexpression in mVECs; Cath L, Cath L overexpression in mVECs; n.s., not significant.